SEC Tracker
Get the app
KURA · XBRL financial data

Kura Oncology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (KURA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers—year only———year only14152117*1821
Cost of goods and services sold——————————00
Research and development2933*36404252*56636864*6562
Selling, general and administrative—year only———year only2325—year only3232
General and administrative1314*18171824*232533———
Total operating expenses4247*54566076*7988101104*——
Operating income (loss)—year only(54)(56)(60)(22)*(65)(73)(80)(86)*(79)(73)
Interest expense00*0000*0000*00
Income tax expense (benefit)—year only———year only00*0*0*00
Net income (loss)(39)(43)*(50)(51)(54)(19)*(57)(66)(74)(81)*(73)(68)
Earnings per share, basic USD per share(0.50)(0.55)*(0.59)(0.59)(0.63)(0.22)*(0.66)(0.75)(0.85)(0.92)*(0.83)(0.77)
Earnings per share, diluted USD per share(0.50)(0.55)*(0.59)(0.59)(0.63)(0.22)*(0.66)(0.75)(0.85)(0.92)*(0.83)(0.77)
Weighted average shares, basic millions of shares7777*84878787*87888888*8989
Weighted average shares, diluted millions of shares7777*84878787*87888888*8989

Balance sheet

CSV

Fiscal quarters (KURA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents29374245492245182951493970
Marketable securities424387486446406503607549454518542449
Accounts receivable—————249536999
Inventory—————0———012
Prepaid and other current assets79118817172535323328
Total current assets460432538500463745724660621709624559
Property and equipment, net222212247888
Right-of-use asset777666888777
Total assets474449554515479760744682649738653588
Accounts payable228231525572
Current portion of long-term debt———1232340—4
Total current liabilities28353233407990107121117101118
Long-term debt99998787510106
Lease liability, non-current66665588891313
Total liabilities4452494955347379377407564545539
Accumulated deficit(679)(721)(771)(822)(876)(895)(953)(1,019)(1,093)(1,174)(1,247)(1,316)
Total stockholders' equity43039750546642441436430524317410848
Total liabilities and equity474449554515479760744682649738653588
Common shares outstanding (cover page) millions of shares747676777881878787888989

Cash flows

CSV

Fiscal quarters (KURA's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(39)(43)*(50)(51)(54)(19)*(57)(66)(74)(81)*(73)(68)
Stock-based compensation77*9889*87*11*11*88*
Net cash from operating activities(29)*(34)*(49)(43)*(43)*year only(72)(29)*(81)*117*(86)(63)*
Purchases of property and equipment0*0*00*0*0*01*3*2*01*
Net cash from investing activities9*42*(95)43*46*(95)*(101)59*94*(65)*(24)92*
Net cash from financing activities0*1*1483*2*1*01*0*1*01*
Net change in cash(20)*9*44*4*175*(173)31*13*54*(110)31*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Kura Oncology7021(63)*89.0M8.3 quarters 10-QJun 30, 2026
Myriad Genetics115191(8.3)*95.6M13.9 quarters 10-QJun 30, 2026
KalVista Pharmaceuticals21441(14)53.2M19.7 quarters 10-QMar 31, 2026
Arbutus Biopharma191(6)*197.8M15.4 quarters 10-QJun 30, 2026
Arvinas880.5(10)*65.5M13.0 quarters 10-QSep 30, 2026
aTYR PHARMA16not reported(9.4)*98.1M6.1 quarters 10-QJun 30, 2026
Elite Pharmaceuticals3932101.1B— 10-QJun 30, 2026
Iovance Biotherapeutics11199(61)*453.0M4.9 quarters 10-QJun 30, 2026
Opko Health301164(44)*746.3M6.9 quarters 10-Q/AJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.